<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01394952</url>
  </required_header>
  <id_info>
    <org_study_id>13438</org_study_id>
    <secondary_id>H9X-MC-GBDJ</secondary_id>
    <nct_id>NCT01394952</nct_id>
  </id_info>
  <brief_title>Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)</brief_title>
  <acronym>REWIND</acronym>
  <official_title>The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular
      events and other serious outcomes in persons with type 2 diabetes, when added to their
      anti-hyperglycemic regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2011</start_date>
  <completion_date type="Actual">August 21, 2018</completion_date>
  <primary_completion_date type="Actual">August 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)</measure>
    <time_frame>From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)</time_frame>
    <description>The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite endpoint) was evaluated using time-to-event analysis. The primary analysis model was a Cox proportional hazards regression model for the time to the first occurrence of a primary endpoint event, with treatment as a fixed effect using the intent-to-treat population. The number of participants who experienced a primary cardiovascular (CV) endpoint event is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke, Individually</measure>
    <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
    <description>The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (individually) was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. Death from CV causes is defined as a death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, or death due to other CV causes. The number of participants who experienced an event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Event for Time to All-cause Mortality</measure>
    <time_frame>From randomization to study completion (Median Follow-Up of 5.4 Years)</time_frame>
    <description>The time to all-cause mortality was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of the Composite Microvascular Endpoint</measure>
    <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
    <description>The time from randomization to first occurrence of the composite microvascular endpoint was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The composite microvascular endpoint is defined as diabetic retinopathy requiring laser therapy, vitrectomy, or anti-vascular endothelial growth factor therapy (VEGF), clinical proteinuria, a greater than equal â‰¥ 30% decline in estimated glomerular filtration rate, or need for chronic renal replacement therapy. The number of participants who experienced the composite microvascular endpoint event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced An Event for Time to First Occurrence After Randomization of Heart Failure Requiring Hospitalization or an Urgent Heart Failure Clinic Visit</measure>
    <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
    <description>The time to first occurrence after randomization of heart failure requiring hospitalization or an urgent heart failure clinic visit was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina</measure>
    <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
    <description>Time to first occurrence after randomization of first hospitalization for unstable angina was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9901</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered once weekly, subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered once weekly, subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>1.5 mg Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes with Hemoglobin A1c equal to or less than 9.5% (equal to or less than
             81 mmol/mol)

          -  Anti-hyperglycemic drug naive or treated with up to 2 oral hyperglycemic drugs with or
             without a glucagon-like peptide-1analog or basal insulin, or basal insulin alone

          -  On stable antihyperglycemic regimen for at least 3 months

          -  Age equal to or greater than 50 years with established clinical vascular disease, or
             age equal to or greater than 55 years and subclinical vascular disease or age equal to
             or greater than 60 years and at least 2 or more cardiovascular risk factors

        Exclusion Criteria:

          -  Uncontrolled diabetes requiring immediate therapy

          -  History of severe hypoglycemia in past year

          -  Acute coronary or cerebrovascular event within past 2 months

          -  Planned or anticipated revascularization procedure

          -  History of pancreatitis, hepatic insufficiency , chronic renal failure or of C-cell
             thyroid disorder

          -  Pregnancy or planned pregnancy during the trial period

          -  Completed or withdrawn from any study investigating dulaglutide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon - Fri 9 AM - 5PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pell City</city>
        <state>Alabama</state>
        <zip>35128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlingame</city>
        <state>California</state>
        <zip>94010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90333</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plant City</city>
        <state>Florida</state>
        <zip>33563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fresh Meadows</city>
        <state>New York</state>
        <zip>11365</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <zip>14787</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <zip>29576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79423</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burke</city>
        <state>Virginia</state>
        <zip>22015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bahia Blanca</city>
        <zip>8000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1119ACN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cipolletti</city>
        <zip>8324</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ciudad De Parana</city>
        <zip>E3100BBJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Coronel Suarez</city>
        <zip>B7540GHD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Corrientes</city>
        <zip>3400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>CÃ³rdoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Junin</city>
        <zip>B6000BHA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Plata</city>
        <zip>B1900AVS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mar Del Plata</city>
        <zip>B7600FZN</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Merlo</city>
        <zip>B1722COV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quilmes</city>
        <zip>1878</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rafaela Santa Fe</city>
        <zip>S2300MMA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salta</city>
        <zip>CP4400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <zip>T4000NIL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Nicolas</city>
        <zip>2900</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santa Fe</city>
        <zip>S2000FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Venado Tuerto</city>
        <zip>S2600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villa Maria</city>
        <zip>X5900JKA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Zarate</city>
        <zip>2800</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Milton</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Elizabeth Vale</city>
        <state>South Australia</state>
        <zip>5112</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Heidelberg Heights</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belo Horizonte</city>
        <zip>30150240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brasilia</city>
        <zip>70390903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Campina Grande Do Sul</city>
        <zip>83430000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Campinas</city>
        <zip>13020421</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Curitiba</city>
        <zip>80010-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90110-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20211-340</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sao Jose Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>SÃ£o Paulo</city>
        <zip>04025-011</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Uberaba</city>
        <zip>38025-260</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Votuporanga</city>
        <zip>15500-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sofia</city>
        <zip>1142</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3G 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Spruce Grove</city>
        <state>Alberta</state>
        <zip>T7X 2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 0R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6S 0C9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 7L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <zip>M9R 4E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8S 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L6B 0P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1J 2K1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 1A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <zip>K7A 4W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Thornhill</city>
        <state>Ontario</state>
        <zip>L4J1W3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y6S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <zip>J2G 8Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7T 2P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1N 4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 4J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ville De Quebec</city>
        <state>Quebec</state>
        <zip>G1L 3L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ville St-Laurent</city>
        <state>Quebec</state>
        <zip>H4T 1Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Esaskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7K 3H3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osomo</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Providencia</city>
        <zip>7500520</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Santiago</city>
        <zip>2570017</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Temuco</city>
        <zip>4781173</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Armenia</city>
        <zip>63001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barranquilla</city>
        <zip>1569</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barrio Maridias</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bogota</city>
        <zip>80CO</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cartagena</city>
        <zip>130010</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>El Espinal</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Floridablanca</city>
        <zip>68276</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manizales</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Medellin</city>
        <zip>5001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pereira</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brno</city>
        <zip>66250</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chomutov</city>
        <zip>43002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Havirov</city>
        <zip>73601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jinocany</city>
        <zip>25225</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ostrava</city>
        <zip>70200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Prague</city>
        <zip>181 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pribram</city>
        <zip>261 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valasske Klobouky</city>
        <zip>76601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Berlin</city>
        <zip>13158</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Burg/Spreewald</city>
        <zip>03096</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dippoldiswalde</city>
        <zip>01744</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>DÃ¼sseldorf</city>
        <zip>40210</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Haag</city>
        <zip>83527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ingelheim</city>
        <zip>55218</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>KÃ¼nzing</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leipzig</city>
        <zip>04107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Riesa</city>
        <zip>01587</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saarlouis</city>
        <zip>66740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Speyer</city>
        <zip>67346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78048</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Balatonfured</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaposvar</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Szekszard</city>
        <zip>7100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Busan</city>
        <zip>602-715</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daegu</city>
        <zip>705-718</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goyang</city>
        <zip>410-773</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guri City</city>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV -5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jelgava</city>
        <zip>LV 3000</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Liepaja</city>
        <zip>LV3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Limbazi</city>
        <zip>LV-4001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ogre</city>
        <zip>LV-5001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Riga</city>
        <zip>LV-1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tukums</city>
        <zip>LV-3101</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valmiera</city>
        <zip>LV4201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaunas</city>
        <zip>LT50184</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT94231</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vilniuslt</city>
        <zip>LT03116</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20234</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cuernavaca</city>
        <zip>62250</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Culiacan</city>
        <zip>80020</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guadalajara</city>
        <zip>44860</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mexico City</city>
        <zip>06090</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Monterrey</city>
        <zip>64620</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tijuana</city>
        <zip>22329</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tlalpan</city>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Toluca</city>
        <zip>50010</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Veracruz</city>
        <zip>91910</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Auckland</city>
        <zip>1640</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beckenham, Christchurch</city>
        <zip>8024</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dunedin</city>
        <zip>9012</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hastings</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Papamoa</city>
        <zip>3118</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Roslyn</city>
        <zip>4414</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rotorua</city>
        <zip>3010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Waitakere</city>
        <zip>0612</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Westown</city>
        <zip>4310</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bialystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Losice</city>
        <zip>08200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Poznan</city>
        <zip>61-655</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pulawy</city>
        <zip>24100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sobotka</city>
        <zip>55050</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Warsaw</city>
        <zip>03003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bayamon</city>
        <zip>00960</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Manati</city>
        <zip>00674</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>San Juan</city>
        <zip>00917-3104</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alba Lulia</city>
        <zip>510053</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bacau</city>
        <zip>600164</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Brasov</city>
        <zip>500365</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bucharest</city>
        <zip>010507</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400349</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Deva</city>
        <zip>330084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Galati</city>
        <zip>800371</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Maramures</city>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oradea</city>
        <zip>410169</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Pitesti</city>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ploiesti</city>
        <zip>100163</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Satu Mare</city>
        <zip>440055</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sibiu</city>
        <zip>550245</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194156</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Volgograd</city>
        <zip>400138</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Benoni</city>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cape Town</city>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Die Wilgers Ext 14</city>
        <zip>0041</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grassy Park</city>
        <zip>7941</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lynnwood Ridge</city>
        <zip>0040</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lyttleton</city>
        <zip>0140</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Parow</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rondebosh</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Somerset West</city>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Soweto</city>
        <zip>2013</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tongaat</city>
        <zip>4400</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Worcester</city>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alicante</city>
        <zip>03450</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Alzira</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Centelles</city>
        <zip>08540</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Palma De Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Segovia</city>
        <zip>40002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vic</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aneby</city>
        <zip>57893</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Goteborg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>HÃ¤rnÃ¶sand</city>
        <zip>87182</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Koping</city>
        <zip>73181</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ljungby</city>
        <zip>341 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ostersund</city>
        <zip>83183</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Skelleftea</city>
        <zip>93186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vaxjo</city>
        <zip>35185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>VÃ¤llingby</city>
        <zip>16268</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kaohsiung Hsien</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sindian City</city>
        <zip>23148</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Taichung City</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bath</city>
        <state>Avon</state>
        <zip>BA2 3HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Middlesbrough</city>
        <state>Cleveland</state>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU3 2RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oldham</city>
        <state>Lancashire</state>
        <zip>OL1 2JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT16 0TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ayr</city>
        <state>Scotland</state>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dundee</city>
        <state>Scotland</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Inverness</city>
        <state>Scotland</state>
        <zip>IV2 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Antrim</city>
        <zip>BT412RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bath</city>
        <zip>BA1 2SR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Londonderry</city>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>India</country>
    <country>Peru</country>
  </removed_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2011</study_first_posted>
  <results_first_submitted>August 9, 2019</results_first_submitted>
  <results_first_submitted_qc>September 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2019</results_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Dulaglutide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT01394952/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 6, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT01394952/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized to either placebo or Dulaglutide. Completers included participants for whom vital status was ascertained during the study close-out period and endpoint completers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo was administered once weekly, subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Dulaglutide</title>
          <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4952"/>
                <participants group_id="P2" count="4949"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="4949"/>
                <participants group_id="P2" count="4943"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4935"/>
                <participants group_id="P2" count="4932"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo was administered once weekly, subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Dulaglutide</title>
          <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4952"/>
            <count group_id="B2" value="4949"/>
            <count group_id="B3" value="9901"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2315"/>
                    <measurement group_id="B2" value="2330"/>
                    <measurement group_id="B3" value="4645"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2637"/>
                    <measurement group_id="B2" value="2619"/>
                    <measurement group_id="B3" value="5256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="6.5"/>
                    <measurement group_id="B2" value="66.2" spread="6.5"/>
                    <measurement group_id="B3" value="66.2" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2283"/>
                    <measurement group_id="B2" value="2306"/>
                    <measurement group_id="B3" value="4589"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2669"/>
                    <measurement group_id="B2" value="2643"/>
                    <measurement group_id="B3" value="5312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="124"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="802"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4486"/>
                    <measurement group_id="B2" value="4489"/>
                    <measurement group_id="B3" value="8975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="543"/>
                    <measurement group_id="B2" value="549"/>
                    <measurement group_id="B3" value="1092"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="218"/>
                    <measurement group_id="B2" value="216"/>
                    <measurement group_id="B3" value="434"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="331"/>
                    <measurement group_id="B3" value="677"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3744"/>
                    <measurement group_id="B2" value="3754"/>
                    <measurement group_id="B3" value="7498"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="166"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Puerto Rico is combined with the United States for this study.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="475"/>
                    <measurement group_id="B2" value="468"/>
                    <measurement group_id="B3" value="943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latvia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="137"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="305"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lithuania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="392"/>
                    <measurement group_id="B2" value="393"/>
                    <measurement group_id="B3" value="785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="698"/>
                    <measurement group_id="B2" value="697"/>
                    <measurement group_id="B3" value="1395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="544"/>
                    <measurement group_id="B2" value="541"/>
                    <measurement group_id="B3" value="1085"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="564"/>
                    <measurement group_id="B2" value="564"/>
                    <measurement group_id="B3" value="1128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="372"/>
                    <measurement group_id="B3" value="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="438"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="292"/>
                    <measurement group_id="B2" value="293"/>
                    <measurement group_id="B3" value="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)</title>
        <description>The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite endpoint) was evaluated using time-to-event analysis. The primary analysis model was a Cox proportional hazards regression model for the time to the first occurrence of a primary endpoint event, with treatment as a fixed effect using the intent-to-treat population. The number of participants who experienced a primary cardiovascular (CV) endpoint event is presented.</description>
        <time_frame>From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered once weekly, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide</title>
            <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)</title>
          <description>The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite endpoint) was evaluated using time-to-event analysis. The primary analysis model was a Cox proportional hazards regression model for the time to the first occurrence of a primary endpoint event, with treatment as a fixed effect using the intent-to-treat population. The number of participants who experienced a primary cardiovascular (CV) endpoint event is presented.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="663"/>
                    <measurement group_id="O2" value="594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary CV endpoint</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority was declared if the upper limit of the 2-sided 95.33% confidence interval (CI) of the hazard ratio was below 1.0 (after adjustment for the interim analysis).
Once superiority was achieved for the primary endpoint, multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>0.026</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95.33</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke, Individually</title>
        <description>The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (individually) was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. Death from CV causes is defined as a death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, or death due to other CV causes. The number of participants who experienced an event is presented.</description>
        <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered once weekly, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide</title>
            <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke, Individually</title>
          <description>The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (individually) was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. Death from CV causes is defined as a death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, or death due to other CV causes. The number of participants who experienced an event is presented.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death from CV causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonfatal MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nonfatal stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Death from CV causes</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>0.211</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nonfatal MI</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>0.652</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Nonfatal stroke</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>0.017</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Event for Time to All-cause Mortality</title>
        <description>The time to all-cause mortality was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
        <time_frame>From randomization to study completion (Median Follow-Up of 5.4 Years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered once weekly, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide</title>
            <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Event for Time to All-cause Mortality</title>
          <description>The time to all-cause mortality was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="592"/>
                    <measurement group_id="O2" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to all cause mortality</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>0.067</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of the Composite Microvascular Endpoint</title>
        <description>The time from randomization to first occurrence of the composite microvascular endpoint was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The composite microvascular endpoint is defined as diabetic retinopathy requiring laser therapy, vitrectomy, or anti-vascular endothelial growth factor therapy (VEGF), clinical proteinuria, a greater than equal â‰¥ 30% decline in estimated glomerular filtration rate, or need for chronic renal replacement therapy. The number of participants who experienced the composite microvascular endpoint event is presented.</description>
        <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered once weekly, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide</title>
            <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of the Composite Microvascular Endpoint</title>
          <description>The time from randomization to first occurrence of the composite microvascular endpoint was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The composite microvascular endpoint is defined as diabetic retinopathy requiring laser therapy, vitrectomy, or anti-vascular endothelial growth factor therapy (VEGF), clinical proteinuria, a greater than equal â‰¥ 30% decline in estimated glomerular filtration rate, or need for chronic renal replacement therapy. The number of participants who experienced the composite microvascular endpoint event is presented.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1241"/>
                    <measurement group_id="O2" value="1099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>microvascular endpoint</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>0.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced An Event for Time to First Occurrence After Randomization of Heart Failure Requiring Hospitalization or an Urgent Heart Failure Clinic Visit</title>
        <description>The time to first occurrence after randomization of heart failure requiring hospitalization or an urgent heart failure clinic visit was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
        <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered once weekly, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide</title>
            <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced An Event for Time to First Occurrence After Randomization of Heart Failure Requiring Hospitalization or an Urgent Heart Failure Clinic Visit</title>
          <description>The time to first occurrence after randomization of heart failure requiring hospitalization or an urgent heart failure clinic visit was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="226"/>
                    <measurement group_id="O2" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Heart failure requiring hospitalization or an urgent heart failure clinic visit</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>0.456</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina</title>
        <description>Time to first occurrence after randomization of first hospitalization for unstable angina was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
        <time_frame>From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo was administered once weekly, subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Dulaglutide</title>
            <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina</title>
          <description>Time to first occurrence after randomization of first hospitalization for unstable angina was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.</description>
          <population>All randomized participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4952"/>
                <count group_id="O2" value="4949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hospitalization for unstable angina</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Multiplicity adjustments using the graphical approach were performed for secondary efficacy endpoints in order to control the overall Type I error rate at a 2-sided alpha level of 0.0467.</non_inferiority_desc>
            <p_value>0.413</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Randomization to Study Completion (Up to 7 Years)</time_frame>
      <desc>All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants at risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo was administered once weekly, subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>Dulaglutide</title>
          <description>1.5 mg Dulaglutide was administered once weekly, subcutaneously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="592" subjects_at_risk="4949"/>
                <counts group_id="E2" subjects_affected="536" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2044" subjects_at_risk="4949"/>
                <counts group_id="E2" subjects_affected="1991" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="4949"/>
                <counts group_id="E2" events="30" subjects_affected="29" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anaemia folate deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anaemia of malignant disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin b12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemolytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy mediastinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Normocytic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Splenic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="43" subjects_affected="41" subjects_at_risk="4949"/>
                <counts group_id="E2" events="44" subjects_affected="43" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="59" subjects_affected="53" subjects_at_risk="4949"/>
                <counts group_id="E2" events="40" subjects_affected="39" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="67" subjects_affected="58" subjects_at_risk="4949"/>
                <counts group_id="E2" events="61" subjects_affected="56" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="58" subjects_affected="54" subjects_at_risk="4949"/>
                <counts group_id="E2" events="47" subjects_affected="44" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic valve disease mixed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="79" subjects_affected="62" subjects_at_risk="4949"/>
                <counts group_id="E2" events="107" subjects_affected="90" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="4949"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bifascicular block</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bundle branch block left</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="4949"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="124" subjects_affected="104" subjects_at_risk="4949"/>
                <counts group_id="E2" events="87" subjects_affected="78" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="4949"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="52" subjects_affected="47" subjects_at_risk="4949"/>
                <counts group_id="E2" events="42" subjects_affected="38" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiorenal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="64" subjects_affected="57" subjects_at_risk="4949"/>
                <counts group_id="E2" events="63" subjects_affected="57" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coronary artery perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Defect conduction intraventricular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrocardiac syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metabolic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Microvascular coronary artery disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mitral valve prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mitral valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="4949"/>
                <counts group_id="E2" events="30" subjects_affected="30" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="4949"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nodal rhythm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Right ventricular dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sinoatrial block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tachycardia induced cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomatous polyposis coli</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic granulomatous disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Congenital cerebrovascular anomaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Exomphalos</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Heart disease congenital</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hereditary motor and sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2667"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Vascular malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Deafness neurosensory</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vestibular ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Acromegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cushing's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperaldosteronism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism secondary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypoparathyroidism secondary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Parathyroid disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Primary hyperaldosteronism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thyroiditis subacute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Amblyopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blepharochalasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="4949"/>
                <counts group_id="E2" events="27" subjects_affected="19" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cataract diabetic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dacryostenosis acquired</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Iridodialysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lens dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Macular fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neurotrophic keratopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ophthalmic vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal compartment syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal incarcerated hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Acute abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anal incontinence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dental cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic gastroparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fistula of small intestine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallstone ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal mucocoele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal polyp haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal vascular malformation haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hernial eventration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Heyde's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mechanical ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Megacolon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mesenteric arterial occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Necrotising oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal achalasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Palatal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peritoneal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peritoneal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peritoneal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Portal venous gas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spigelian hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Strangulated umbilical hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Volvulus of small bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Drug effect increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hernia perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metaplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="44" subjects_affected="37" subjects_at_risk="4949"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Strangulated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vascular stent stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Biliary dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholangitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="4949"/>
                <counts group_id="E2" events="28" subjects_affected="25" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="4949"/>
                <counts group_id="E2" events="27" subjects_affected="26" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="49" subjects_at_risk="4949"/>
                <counts group_id="E2" events="43" subjects_affected="42" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder cholesterolosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatorenal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-alcoholic fatty liver</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-alcoholic steatohepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Portal hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post cholecystectomy syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Immunodeficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abscess intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortitis salmonella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Breast cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchitis fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Candiduria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="48" subjects_affected="42" subjects_at_risk="4949"/>
                <counts group_id="E2" events="39" subjects_affected="38" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cellulitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis b</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cystitis escherichia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dengue haemorrhagic fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Echinococciasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2667"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="4949"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Extradural abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="18" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>H1n1 influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatitis b</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatitis c</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatitis e</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatitis infectious mononucleosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Herpes zoster meningoencephalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Herpes zoster pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hydrocele male infected</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2667"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Implant site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Infected skin ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Injection site abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Joint abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Medical device site joint infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2667"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteomyelitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Perihepatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Perineal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Perirectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pharyngeal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="174" subjects_affected="151" subjects_at_risk="4949"/>
                <counts group_id="E2" events="152" subjects_affected="135" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal cyst infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="4949"/>
                <counts group_id="E2" events="33" subjects_affected="30" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="4949"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Skin graft infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Staphylococcal mediastinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Staphylococcal skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Subdiaphragmatic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="65" subjects_affected="61" subjects_at_risk="4949"/>
                <counts group_id="E2" events="78" subjects_affected="64" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary tract infection pseudomonal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="4949"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Viraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Viral myocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Wound sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anastomotic complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="4949"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arterial injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coronary vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Craniofacial fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Delayed recovery from anaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Failure to anastomose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="137" subjects_affected="124" subjects_at_risk="4949"/>
                <counts group_id="E2" events="123" subjects_affected="110" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="4949"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Foreign body in gastrointestinal tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastroenteritis radiation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stoma complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="4949"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="4949"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Incisional hernia, obstructive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intestinal anastomosis complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lumbosacral plexus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post concussion syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural bile leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post procedural swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Postoperative adhesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Postoperative delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Postoperative thoracic procedure complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Procedural hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Radiation pneumonitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="4949"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sciatic nerve injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Scrotal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Stoma site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Suture rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Transfusion-related acute lung injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Traumatic haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Wound secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anticoagulation drug level above therapeutic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood calcitonin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coagulation test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Glycosylated haemoglobin increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Troponin t increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="4949"/>
                <counts group_id="E2" events="24" subjects_affected="23" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fluid overload</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="75" subjects_affected="67" subjects_at_risk="4949"/>
                <counts group_id="E2" events="52" subjects_affected="46" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperosmolar state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="80" subjects_affected="72" subjects_at_risk="4949"/>
                <counts group_id="E2" events="69" subjects_affected="62" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arthrofibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Articular calcification</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bone lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis pyrophosphate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic amyotrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fracture malunion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gouty tophus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="4949"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Joint ankylosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Joint noise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neuropathic arthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteitis deformans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="128" subjects_affected="110" subjects_at_risk="4949"/>
                <counts group_id="E2" events="155" subjects_affected="136" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Plantar fascial fibromatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rheumatic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="4949"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spondylolysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vertebral osteophyte</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="4949"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adenosquamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adrenal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anaplastic astrocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Astrocytoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma stage i</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma stage ii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>B-cell small lymphocytic lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Benign gastric neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Benign hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of adrenal gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bile duct adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Biliary cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma stage i</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bone cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bone neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Borderline ovarian tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Breast cancer stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brenner tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cardiac myxoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2282"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma stage 0</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colon cancer stage ii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colon cancer stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Colorectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ductal adenocarcinoma of pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2282"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Extranodal marginal zone b-cell lymphoma (malt type)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Fibrosarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gallbladder squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic angiosarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Huerthle cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Leiomyosarcoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Liposarcoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage ii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Malignant joint neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Malignant melanoma stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of vater</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Medullary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Meningeal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mesothelioma malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to chest wall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to kidney</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to pelvis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastases to pleura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastatic bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nasal sinus cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2667"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma of the skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage ii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Ovarian cancer stage iii</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Paraganglion neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Penile squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Pericardial effusion malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Phaeochromocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Plasma cell leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="2667"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2667"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage i</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2667"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rectal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal meningioma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spindle cell sarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the cervix</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vagina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the vulva</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Sweat gland tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thymoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tongue carcinoma stage iv</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Transitional cell cancer of the renal pelvis and ureter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tumour of ampulla of vater</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urethral cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2282"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Uterine neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Vascular neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acoustic neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Amputation stump pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carotid arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebellar ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebellar atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral circulatory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="4949"/>
                <counts group_id="E2" events="25" subjects_affected="24" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic hyperglycaemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic hyperosmolar coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic mononeuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Frontal lobe epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhagic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Iiird nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ischaemic cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="4949"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lacunar stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Language disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lumbosacral radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mixed dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Motor neurone disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myelopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neuritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Paralysis recurrent laryngeal nerve</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral nerve paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral sensorimotor neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Piriformis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pseudobulbar palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Quadriplegia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Spinal claudication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="34" subjects_affected="33" subjects_at_risk="4949"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thrombotic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="4949"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Uraemic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vascular encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vascular parkinsonism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vith nerve paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device damage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device loosening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Generalised anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Personality change due to a general medical condition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Psychogenic seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Somatic delusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="74" subjects_affected="67" subjects_at_risk="4949"/>
                <counts group_id="E2" events="72" subjects_affected="61" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atonic urinary bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder neck sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Calculus urethral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>End stage renal disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhage urinary tract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hydroureter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypertensive nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Kidney perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="4949"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pelvi-ureteric obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="4949"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ureteric dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urethral caruncle</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urethral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary bladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="2667"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cervical polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="2282"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Endometrial hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Female genital tract fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Fibrocystic breast disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2667"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Pelvic fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2667"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2667"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2667"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2640"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Uterine disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2282"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2282"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Vaginal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2282"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2303"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2282"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2303"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired diaphragmatic eventration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="4949"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Alveolitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchial polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="45" subjects_affected="35" subjects_at_risk="4949"/>
                <counts group_id="E2" events="32" subjects_affected="25" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="4949"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pharyngeal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pleural thickening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="4949"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="4949"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Respiratory tract oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Restrictive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rhinitis hypertrophic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="24" subjects_affected="19" subjects_at_risk="4949"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypersensitivity vasculitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Ischaemic skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neuropathic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pemphigoid</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pyoderma gangrenosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vasculitic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Diet noncompliance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Organ donor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="4949"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Bleeding varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="4949"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dry gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Essential hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="4949"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="4949"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Iliac artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lymphatic fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Neurogenic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="4949"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="4949"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="4949"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="4949"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Subclavian artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4949"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4949"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4949"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3363" subjects_at_risk="4949"/>
                <counts group_id="E2" subjects_affected="3574" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="417" subjects_affected="368" subjects_at_risk="4949"/>
                <counts group_id="E2" events="427" subjects_affected="363" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="223" subjects_affected="208" subjects_at_risk="4949"/>
                <counts group_id="E2" events="409" subjects_affected="361" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="546" subjects_affected="436" subjects_at_risk="4949"/>
                <counts group_id="E2" events="843" subjects_affected="665" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="150" subjects_affected="147" subjects_at_risk="4949"/>
                <counts group_id="E2" events="331" subjects_affected="291" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="310" subjects_affected="269" subjects_at_risk="4949"/>
                <counts group_id="E2" events="968" subjects_affected="735" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="165" subjects_affected="154" subjects_at_risk="4949"/>
                <counts group_id="E2" events="498" subjects_affected="325" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="554" subjects_affected="421" subjects_at_risk="4949"/>
                <counts group_id="E2" events="528" subjects_affected="408" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="488" subjects_affected="404" subjects_at_risk="4949"/>
                <counts group_id="E2" events="435" subjects_affected="369" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="771" subjects_affected="535" subjects_at_risk="4949"/>
                <counts group_id="E2" events="800" subjects_affected="564" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="589" subjects_affected="407" subjects_at_risk="4949"/>
                <counts group_id="E2" events="533" subjects_affected="368" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="749" subjects_affected="517" subjects_at_risk="4949"/>
                <counts group_id="E2" events="795" subjects_affected="545" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="109" subjects_affected="104" subjects_at_risk="4949"/>
                <counts group_id="E2" events="379" subjects_affected="325" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="445" subjects_affected="315" subjects_at_risk="4949"/>
                <counts group_id="E2" events="190" subjects_affected="158" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1160" subjects_affected="354" subjects_at_risk="4949"/>
                <counts group_id="E2" events="1477" subjects_affected="413" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="469" subjects_affected="389" subjects_at_risk="4949"/>
                <counts group_id="E2" events="446" subjects_affected="371" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="484" subjects_affected="416" subjects_at_risk="4949"/>
                <counts group_id="E2" events="494" subjects_affected="447" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="373" subjects_affected="318" subjects_at_risk="4949"/>
                <counts group_id="E2" events="372" subjects_affected="329" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="280" subjects_affected="245" subjects_at_risk="4949"/>
                <counts group_id="E2" events="296" subjects_affected="260" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="339" subjects_affected="296" subjects_at_risk="4949"/>
                <counts group_id="E2" events="373" subjects_affected="318" subjects_at_risk="4943"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="382" subjects_affected="288" subjects_at_risk="4949"/>
                <counts group_id="E2" events="414" subjects_affected="324" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="263" subjects_affected="259" subjects_at_risk="4949"/>
                <counts group_id="E2" events="241" subjects_affected="232" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="137" subjects_affected="135" subjects_at_risk="2667"/>
                <counts group_id="E2" events="144" subjects_affected="140" subjects_at_risk="2640"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="292" subjects_affected="256" subjects_at_risk="4949"/>
                <counts group_id="E2" events="265" subjects_affected="239" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="491" subjects_affected="432" subjects_at_risk="4949"/>
                <counts group_id="E2" events="405" subjects_affected="345" subjects_at_risk="4943"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>www.ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

